Found 136 clinical trials
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive HR-Positive Metastatic Breast Cancer
HR+/HER2+Human epidermal growth factor receptor 2 positive and hormone receptor positivemetastatic breast cancer is a special subtype of HER2+breast cancer. Conventional guidelines recommend
- 9 views
- 27 Jan, 2021
- 2 locations
Assessing the Immunogenicity of pING-hHER3FL
protein and will be used in a phase I study as immunotherapeutic agent to target cancers that are known to express the human epidermal growth factor receptor HER3. The human epidermal growth factor
- 0 views
- 24 Sep, 2021
- 1 location
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
, pertuzumab, pembrolizumab and weekly paclitaxel (THP-K), or neoadjuvant trastuzumab, pembrolizumab and weekly paclitaxel (TH-K) in chemo naive patients with invasive human epidermal growth factor receptor 2
- 18 views
- 08 Sep, 2021
- 2 locations
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The
- 0 views
- 30 Nov, 2021
- 19 locations
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and fast-growing
- 107 views
- 12 Dec, 2021
- 5 locations
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2
- 5 views
- 25 Nov, 2021
- 1 location
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR
- 0 views
- 04 Jul, 2021
- 1 location
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the
- 47 views
- 19 Dec, 2021
- 13 locations
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This is a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that have select mutations or alterations in human epidermal growth factor receptor
- 8 views
- 26 Dec, 2021
- 32 locations
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have progressed on an aromatase
- 4 views
- 28 Jan, 2021
- 13 locations